Biomarker | Baseline requirement | Placebo (N = 105) | Baricitinib 2 mg (N = 105) | Baricitinib 4 mg (N = 104) |
---|---|---|---|---|
Anti-dsDNA | ≥30 IU/mL | 51 (48.6) | 56 (53.3) | 53 (51.0) |
IgG | No requirement | 101 (96.2) | 99 (94.3) | 96 (92.3) |
C3 | <90 mg/dL | 30 (28.6) | 30 (28.6) | 34 (32.7) |
C4 | <10 mg/dL | 15 (14.3) | 26 (24.8) | 15 (14.4) |
Anti-Sm | ≥30 IU/mL | 12 (11.47) | 7 (6.67) | 9 (8.7) |
aCL IgM | >12 MPL | 20 (19.0) | 22 (20.9) | 22 (21.2) |
aCL IgG | >14 GPL | 10 (9.5) | 10 (9.5) | 5 (4.8) |
aCL IgA | >11 APL | 4 (3.8) | 6 (5.7) | 1 (1.0) |
Anti-RNP | ≥30 IU/mL | 28 (26.7) | 21 (20.0) | 28 (27.0) |
Anti-SSA | >20 IU/mL | 35 (33.3) | 27 (25.7) | 27 (26.0) |
Anti-SSB | >20 IU/mL | 15 (14.3) | 15 (14.3) | 16 (15.3) |